EA025926B1 - Молекулярно-диагностический тест на рак - Google Patents

Молекулярно-диагностический тест на рак Download PDF

Info

Publication number
EA025926B1
EA025926B1 EA201391805A EA201391805A EA025926B1 EA 025926 B1 EA025926 B1 EA 025926B1 EA 201391805 A EA201391805 A EA 201391805A EA 201391805 A EA201391805 A EA 201391805A EA 025926 B1 EA025926 B1 EA 025926B1
Authority
EA
Eurasian Patent Office
Prior art keywords
semantic
expression
exon
completely
cancer
Prior art date
Application number
EA201391805A
Other languages
English (en)
Russian (ru)
Other versions
EA201391805A1 (ru
Inventor
Денис Пол Харкин
Фионнуала Паттерсон
Клэр Триндер
Имонн Дж. О'Брайен
Кэролайн Мичи
Чарли Гурли
Лора А. Хилл
Кэтрин Э. Китинг
Джуд О'Доннелл
Макс Бюлешо
Стив Деаро
Виталий Прутский
Ричард Кеннеди
Тимоти Дэвисон
Андреас Винтер
Эндрена Маккэйвиган
Original Assignee
Олмак Дайэгностикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Олмак Дайэгностикс Лимитед filed Critical Олмак Дайэгностикс Лимитед
Publication of EA201391805A1 publication Critical patent/EA201391805A1/ru
Publication of EA025926B1 publication Critical patent/EA025926B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7014—(Neo)vascularisation - Angiogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201391805A 2011-06-02 2012-06-04 Молекулярно-диагностический тест на рак EA025926B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161492488P 2011-06-02 2011-06-02
PCT/US2012/040805 WO2012167278A1 (en) 2011-06-02 2012-06-04 Molecular diagnostic test for cancer

Publications (2)

Publication Number Publication Date
EA201391805A1 EA201391805A1 (ru) 2014-03-31
EA025926B1 true EA025926B1 (ru) 2017-02-28

Family

ID=47259970

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201391805A EA025926B1 (ru) 2011-06-02 2012-06-04 Молекулярно-диагностический тест на рак
EA201691257A EA201691257A1 (ru) 2011-06-02 2012-06-04 Молекулярно-диагностический тест на рак

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201691257A EA201691257A1 (ru) 2011-06-02 2012-06-04 Молекулярно-диагностический тест на рак

Country Status (13)

Country Link
US (1) US10260097B2 (enExample)
EP (1) EP2715348B1 (enExample)
JP (2) JP6067686B2 (enExample)
KR (1) KR20140044341A (enExample)
CN (1) CN103733065B (enExample)
AU (1) AU2012261820B2 (enExample)
BR (1) BR112013031019A2 (enExample)
CA (1) CA2838086A1 (enExample)
EA (2) EA025926B1 (enExample)
IL (1) IL229681A0 (enExample)
MX (1) MX2013014065A (enExample)
SG (2) SG195208A1 (enExample)
WO (1) WO2012167278A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025926B1 (ru) 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест на рак
EP2667193A1 (en) * 2012-05-23 2013-11-27 Université d'Aix-Marseille MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients
WO2014055398A1 (en) 2012-10-05 2014-04-10 Siemens Healthcare Diagnostics Inc. Method for detecting an increased risk or incidence of colorectal cancer
AU2013353839A1 (en) * 2012-12-03 2015-06-18 Almac Diagnostics Limited Molecular diagnostic test for cancer
GB201313342D0 (en) * 2013-07-26 2013-09-11 Cancer Rec Tech Ltd Biomarkers
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
GB201409479D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
GB201409478D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Pro-angiogenic signature
GB201409476D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular subtype for use in prognosis
WO2016011052A1 (en) * 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US20170247758A1 (en) * 2014-08-18 2017-08-31 Drexel University Methods, computer-readable media, and systems for assessing samples and wounds, predicting whether a wound will heal, and monitoring effectiveness of a treatment
KR20160101706A (ko) * 2015-02-17 2016-08-25 싸이퍼롬, 인코퍼레이티드 자궁수축억제제 부작용 방지를 위한 개인별 단백질 손상 정보 기반의 자궁수축억제제 선택 방법
CN105160208A (zh) * 2015-05-29 2015-12-16 杭州奥视图像技术有限公司 用于疾病亚型问题的基于网络的聚类方法
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
HRP20202019T1 (hr) 2015-07-01 2021-04-30 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
US10650325B2 (en) * 2015-07-31 2020-05-12 Microsoft Technology Licensing, Llc Deterministic message distribution
CA2996426A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
ES2908848T3 (es) * 2016-01-25 2022-05-04 Sanofi Sa Método de predicción del resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer midiendo el nivel de un biomarcador de plasma
US20190127805A1 (en) * 2016-03-15 2019-05-02 Almac Diagnostics Limited Gene signatures for cancer detection and treatment
JP6899848B2 (ja) 2016-12-28 2021-07-07 公益財団法人がん研究会 抗ｖｅｇｆｒ−２抗体医薬品の治療効果を予測するバイオマーカー、検査方法、及び検査キット
CN107037210A (zh) * 2017-04-05 2017-08-11 北京蛋白质组研究中心 Thbs2蛋白检测物在制备肝细胞癌诊断试剂盒中的应用
US20200200760A1 (en) * 2017-05-16 2020-06-25 Lankenau Institute Of Medical Research Compositions comprising ligands to rhob protein and the uses thereof
US10311967B2 (en) 2017-06-13 2019-06-04 Bostongene Corporation Systems and methods for generating, visualizing and classifying molecular functional profiles
US20180365372A1 (en) * 2017-06-19 2018-12-20 Jungla Inc. Systems and Methods for the Interpretation of Genetic and Genomic Variants via an Integrated Computational and Experimental Deep Mutational Learning Framework
EP3461916A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
WO2019165366A1 (en) * 2018-02-23 2019-08-29 Beth Israel Deaconess Medical Center Drug efficacy evaluations
US11681953B2 (en) * 2018-04-13 2023-06-20 Freenome Holdings, Inc. Machine learning implementation for multi-analyte assay development and testing
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
CA3107571A1 (en) * 2018-06-27 2020-01-02 Qcdx Llc Biological sample holder and handler
CN109585011A (zh) * 2018-10-26 2019-04-05 朱海燕 胸痛患者的病症诊断方法及机器可读存储介质
JP2022513038A (ja) * 2018-11-14 2022-02-07 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合薬を使用する癌の治療方法
US20210118527A1 (en) * 2019-07-22 2021-04-22 Mission Bio, Inc. Using Machine Learning to Optimize Assays for Single Cell Targeted DNA Sequencing
KR102289533B1 (ko) * 2019-08-19 2021-08-17 주식회사 테라젠바이오 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램
US11049590B1 (en) 2020-02-12 2021-06-29 Peptilogics, Inc. Artificial intelligence engine architecture for generating candidate drugs
BR112022022338A2 (pt) * 2020-05-04 2023-01-10 Amgen Inc Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso
TW202208355A (zh) * 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
CN112489800B (zh) * 2020-12-03 2024-05-28 安徽医科大学第一附属医院 一种前列腺癌患者的预后评估系统及其应用
CN116312814B (zh) * 2021-12-02 2024-09-27 复旦大学 一种肺腺癌分子分型模型的构建方法、设备、装置以及试剂盒
CN114624441B (zh) * 2022-03-04 2025-07-18 中国人民解放军空军军医大学 跨膜蛋白43作为胰腺癌肿瘤诊断标志物的应用
CN115902223B (zh) * 2022-11-15 2025-08-26 中国人民解放军空军军医大学 蛋白生物标志物在胃癌诊断中的应用
CN116863995B (zh) * 2023-08-29 2024-05-14 北京大学第一医院 Alpk2，itga11，esyt1，cdh17在预测药物出血中的应用
CN118393140B (zh) * 2024-04-24 2025-04-11 英科众康(厦门)科技有限公司 基于适配体/抗体新型夹心式介导的检测技术在泛癌标志物c1qc诊断中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022129A1 (en) * 2007-08-13 2009-02-19 Almac Diagnostics Limited A 3' -based sequencing approach for microarray manufacture
US20090304594A1 (en) * 2005-12-05 2009-12-10 Fantin Valeria R Methods for Predicting Treatment Response Based On the Expression Profiles of Protein and Transcription Biomarkers
WO2011005273A1 (en) * 2009-07-06 2011-01-13 Aveo Pharmaceuticals Inc. Tivozanib response prediction

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
WO1993020236A1 (en) 1992-04-03 1993-10-14 Applied Biosystems, Inc. Probe composition and method
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
US6946442B2 (en) 1994-11-30 2005-09-20 Asif Syed Ahmed Method of hastening cervical ripening
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
JP2002515738A (ja) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド 核酸分析法
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6998234B2 (en) 2000-11-03 2006-02-14 Oncotech, Inc. Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
WO2003096981A2 (en) 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
AU2003281325A1 (en) 2002-07-02 2004-01-23 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
KR20160014775A (ko) * 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
WO2004108896A2 (en) 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
EP1704250B1 (en) 2003-12-31 2012-09-19 The Penn State Research Foundation Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
EP1756306A2 (en) * 2004-05-14 2007-02-28 Ludwig Institute For Cancer Research Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib
MX2007000944A (es) * 2004-07-23 2007-04-13 Astrazeneca Ab Metodo para pronosticar la sensibilidad de un tumor a farmacos del receptor erbb.
US20060134663A1 (en) 2004-11-03 2006-06-22 Paul Harkin Transcriptome microarray technology and methods of using the same
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
ATE477495T1 (de) * 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
WO2007015947A2 (en) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
EP1926996B1 (en) * 2005-09-20 2011-11-09 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
AU2007211085A1 (en) 2006-01-27 2007-08-09 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
CA2639070A1 (en) * 2006-04-13 2007-11-01 Oncomethylime Sciences S.A. Novel tumour suppressor
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN101541977A (zh) 2006-09-19 2009-09-23 诺瓦提斯公司 用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物
WO2009042814A1 (en) 2007-09-25 2009-04-02 Minerva Biotechnologies Corp. Early diagnosis and treatment of drug resistance in muc1-positive cancer
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
MX2010005057A (es) 2007-11-09 2010-05-19 Genentech Inc Metodos y composiciones para uso de diagnostico en pacientes de cancer.
US20100279892A1 (en) 2007-12-07 2010-11-04 Mcweeney Shannon K Methods to determine if a subject will respond to a bcr-abl inhibitor
US8114593B2 (en) 2008-03-12 2012-02-14 University Of Medicine And Dentistry Of New Jersey Cancer biomarker genes and gene products and methods for using the same
JP2011525106A (ja) 2008-06-04 2011-09-15 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 瀰漫性ｂ大細胞型リンパ腫のマーカーおよびその使用方法
EP2294420B8 (en) 2008-06-06 2015-10-21 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Survival predictor for diffuse large B cell lymphoma
AU2009270851A1 (en) * 2008-07-16 2010-01-21 Dana-Farber Cancer Institute, Inc. Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof
JP5606438B2 (ja) 2008-07-23 2014-10-15 エフ．ホフマン−ラ ロシュ アーゲー 抗血管新生療法を受容可能な被験体の同定
EP2706358A3 (en) 2008-12-23 2014-05-07 Merck Patent GmbH Biomarkers for inhibitors with anti-angiogenic activity
WO2010088688A2 (en) * 2009-02-02 2010-08-05 Biotheranostics, Inc. Diagnosis of in situ and invasive breast cancer
SG10201401722XA (en) 2009-05-01 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy
JP5606537B2 (ja) * 2009-09-17 2014-10-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌患者における診断使用のための方法及び組成物
MY166040A (en) 2010-09-15 2018-05-21 Almac Diagnostics Ltd Molecular diagnostic test for cancer
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
US20150024952A1 (en) 2010-12-28 2015-01-22 Arlet Alarcon Molecular profiling for cancer
EA025926B1 (ru) 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест на рак
BR112014017320A2 (en) 2012-01-13 2018-05-29 Genentech, Inc method for determining whether a patient is prone to respond to treatment with a vegf antagonist, method for optimizing the therapeutic efficacy of a vegf antagonist, method for selecting a therapy, method for identifying a biomarker, and method for diagnosing an angiogenic disorder
EP2667193A1 (en) 2012-05-23 2013-11-27 Université d'Aix-Marseille MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients
AU2013353839A1 (en) 2012-12-03 2015-06-18 Almac Diagnostics Limited Molecular diagnostic test for cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304594A1 (en) * 2005-12-05 2009-12-10 Fantin Valeria R Methods for Predicting Treatment Response Based On the Expression Profiles of Protein and Transcription Biomarkers
WO2009022129A1 (en) * 2007-08-13 2009-02-19 Almac Diagnostics Limited A 3' -based sequencing approach for microarray manufacture
WO2011005273A1 (en) * 2009-07-06 2011-01-13 Aveo Pharmaceuticals Inc. Tivozanib response prediction

Also Published As

Publication number Publication date
JP6067686B2 (ja) 2017-01-25
BR112013031019A2 (pt) 2017-03-21
CA2838086A1 (en) 2012-12-06
SG10201604497UA (en) 2016-07-28
CN103733065B (zh) 2017-12-15
WO2012167278A1 (en) 2012-12-06
US10260097B2 (en) 2019-04-16
IL229681A0 (en) 2014-01-30
MX2013014065A (es) 2014-06-23
SG195208A1 (en) 2013-12-30
EP2715348A4 (en) 2015-10-07
US20140342924A1 (en) 2014-11-20
JP2017079772A (ja) 2017-05-18
EP2715348B1 (en) 2019-04-10
NZ618191A (en) 2015-04-24
KR20140044341A (ko) 2014-04-14
EA201691257A1 (ru) 2017-02-28
AU2012261820B2 (en) 2017-01-19
EP2715348A1 (en) 2014-04-09
JP2014516552A (ja) 2014-07-17
EA201391805A1 (ru) 2014-03-31
CN103733065A (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
EA025926B1 (ru) Молекулярно-диагностический тест на рак
AU2011302004B2 (en) Molecular diagnostic test for cancer
US20160002732A1 (en) Molecular diagnostic test for cancer
AU2012261820A1 (en) Molecular diagnostic test for cancer
JP2016536001A (ja) 肺がんのための分子診断試験
US20160222460A1 (en) Molecular diagnostic test for oesophageal cancer
JP2017506506A (ja) 抗血管新生薬への応答およびがんの予後の予測のための分子診断試験
US20130323744A1 (en) Signatures and Determinants Associated with Cancer and Methods of Use Thereof
WO2013190092A1 (en) Gene signatures for copd diagnosis
US20230399701A1 (en) Prognostic gene signature and method for diffuse large b-cell lymphoma prognosis and treatment
WO2018174861A1 (en) Methods and compositions for detecting early stage breast cancer with rna-seq expression profiling
CN113234823A (zh) 胰腺癌预后风险评估模型及其应用
JP2024540836A (ja) 肺癌の予測及びその利用
US20130073213A1 (en) Gene Expression-Based Differential Diagnostic Model for Rheumatoid Arthritis
Glas et al. MammaPrint® translating research into a diagnostic test
EP2607494A1 (en) Biomarkers for lung cancer risk assessment
JP2025534223A (ja) タバコ使用状態を査定する方法

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU